Dr. Isidro B. Salusky, a distinguished professor of pediatrics at the David Geffen School of Medicine at UCLA, wrote an editorial in the New England Journal of Medicine describing a phase 3 trial as a potentially giant step forward for treating children with achondroplasia. ^[1] Trial results published in June 2026 in the New England Journal of Medicine suggest that once-daily oral infigratinib treatment for 52 weeks resulted in a significantly greater increase in growth from baseline than placebo treatment. ^[2] Andrea Krenek, a postdoctoral researcher at Stanford University School of Medicine, stated that cabbage is a potent source of nutrients with high concentrations of vitamins, fiber, and antioxidants. ^[3] A phase 3 trial assessed the effect of administering infigratinib, an oral treatment option, to 114 randomly assigned children with achondroplasia ages 3-17. ^[4] Andrea Krenek noted that cabbage is beneficial whether consumed fresh, cooked, or fermented. ^[5] Research indicates that higher consumption of prebiotics is associated with better blood sugar control, a stronger immune system, and a lower risk of colorectal cancer. ^[6] Zhaoping Li, head of the clinical nutrition division at UCLA Health, stated that cabbage fiber acts as a prebiotic to feed beneficial gut bacteria and increase diversity. ^[7]